ACUTE MEGACARYOBLASTIC LEUKEMIA IN CHILDREN: DIAGNOSTICS AND MRD MONITORING
| Autor: | Aleksander Popa, NN Tupitsyn, Aleksandra Palladina, Natalya Kupryshina |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Oncology
medicine.medical_specialty Down syndrome business.industry CD33 CD34 Myeloid leukemia Hematology medicine.disease Minimal residual disease Acute megakaryoblastic leukemia Leukemia Immunophenotyping hemic and lymphatic diseases Internal medicine medicine Immunology and Allergy Diseases of the blood and blood-forming organs RC633-647.5 business |
| Zdroj: | Hematology, Transfusion and Cell Therapy, Vol 43, Iss, Pp S25-(2021) |
| ISSN: | 2531-1379 |
| Popis: | Objective Acute megakaryoblastic leukemia (AMKL) is a rare subtype of acute myeloid leukemia (AML) associated with poor prognosis for all patients except children with t(1;22) or Down syndrome. The frequency of complete remission in case of AMKL is comparable to the frequency of it in other variants of AML but the median survival is much lower. This determines the necessity of more thorough evaluation of treatment effect using flow cytometry accessment of minimal residual disease (MRD). Methodology The clinical and immunological profile of 8 girls and 9 boys with de novo AMKL between the ages of 3 months–11 years old was analyzed. The primary leucocytosis median was 10,25; only one patient had hyperleukocytosis (53х109/l) at presentation.The measurement of MRD was performed in 6 patients using multiparameter flow cytometry. The measurement of MRD performed after induction therapy on the basis of megakaryocytic markers, weak CD45 expression using the initial iimmunophenotype patterns. Results Adequate measurement of the level of MRD had required extensive diagnostic immunophenotyping in order to determine the aberration of megakaryoblasts. CD9(83,3%), CD33(75%), CD34(60%), CD13(50%) apart from megakaryocyte markers (100%) were most common for blast cells in case of AMKL. The expression of CD7 antigen was as frequent as of CD117-40%. The MRD level ranged from completely negative (0%; 0.006%) to evident (1.05%). Conclusion The detection of residual tumor megakaryoblasts in AML M7 using flow cytometry is a promising method for assessing the effect of therapy. Adequate measurement of MRD requires detailed immunophenotyping in the diagnosis to determine the aberrations of megacaryoblasts immunophenotype. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|